Journal
ONCOLOGIST
Volume 12, Issue 12, Pages 1425-1432Publisher
WILEY
DOI: 10.1634/theoncologist.12-12-1425
Keywords
hepatocellular carcinoma; liver neoplasms; chemoembolization; drug therapy; doxorubicin; sorafenib; bevacizumab; erlotinib
Categories
Funding
- NATIONAL CANCER INSTITUTE [K23CA118431] Funding Source: NIH RePORTER
- NCI NIH HHS [5 K23 CA118431-02] Funding Source: Medline
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is a disease that requires multidisciplinary management. There has been no widely accepted standard for systemic therapy for this disease until recently. This article briefly discusses the management of earlier stage HCC, then focuses on newer agents with promise, particularly sorafenib, a drug that appears to be the new standard of care for advanced disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available